未登录
分享
收藏
分享
收藏
分享
收藏
分享
收藏EFFICACY AND SAFETY OF SIMEPREVIR AND SOFOSBUVIR WITH AND WITHOUT RIBAVIRIN FOR 12 WEEKS IN SUBJECTS WITH RECURRENT GENOTYPE 1 HEPATITIS C POST-ORTHOTOPIC LIVER TRANSPLANT: THE GALAXY STUDY
O'Leary, J. G.; Brown, K.; Burton, J., Jr.; Firpi-Morell, R.; Fontana, R. J.; Muir, A.; O'Brien, C.; Rabinovitz, M.; Reddy, K. Rajender; Ryan, R.; Shprecher, A.; Villadiego, S.; Prabhakar, A.; Brown, R. S., Jr.
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to pegIFN/RBV: One-year results
Afdhal, N.; O'Brien, C.; Godofsky, E.; Rodriguez-Torres, M.; Pappas, S. C.; Lawitz, E.; Pockros, P.; Sulkowski, M.; Jacobson, I.; Chao, G.; Knox, S.; Pietropaolo, K.; Brown, N. A.
分享
收藏
分享
收藏
分享
收藏
分享
收藏Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels
Pockros, PJ; Diago, M; Gane, E; Reddy, KR; Prati, D; Shiffman, ML; Farci, P; O'Brien, C; Lardelli, P; Lamour, F; Zeuzem, S
分享
收藏
分享
收藏
分享
收藏